Printer Friendly

SUMMIT RECEIVES FDA CLEARANCE TO SELL OMNIMED HOLMIUM LASER SYSTEM IN THE UNITED STATES

 SUMMIT RECEIVES FDA CLEARANCE TO SELL OMNIMED
 HOLMIUM LASER SYSTEM IN THE UNITED STATES
 WALTHAM, Mass., June 22 /PRNewswire/ -- Summit Technology, Inc. (NASDAQ: BEAM) announced today that the Food & Drug Administration has cleared the company's OmniMed(tm) Holmium Laser System for commercial marketing and sale in the United States for treatment of glaucoma. Glaucoma is the second leading cause of blindness in the United States. This clearance is pursuant to Section 510(k) of the United States Food and Drug law.
 Summit Technology, Inc. has established the leadership position in designing, manufacturing and marketing ophthalmic excimer laser systems. A major focus of the company's business is in ophthalmology where applications have been developed for the treatment of common vision disorders such as nearsightedness, farsightedness, astigmatism, glaucoma and certain corneal irregularities due to disease or injury.
 -0- 6/22/92
 /CONTACT: Paula Rainville of Summit Technology, 617-890-1234/
 (BEAM) CO: Summit Technology ST: Massachusetts IN: MTC SU:


PB -- NE007 -- 2262 06/22/92 09:31 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 22, 1992
Words:164
Previous Article:HILLHAVEN FILES $65 MILLION OF CONVERTIBLE SUBORDINATED DEBENTURES
Next Article:UNIVERSAL STANDARD ACQUIRES LABORATORY OF CLINICAL MEDICINE, INC.
Topics:


Related Articles
SUMMIT TECHNOLOGY RECEIVES IDE FROM FDA FOR TREATMENT OF ASTIGMATISM WITH HOLMIUM LASER SYSTEM
SUMMIT TECHNOLOGY ANNOUNCES FDA APPROVAL TO BEGIN SECOND PHASE OF U.S. CLINICAL TRIALS USING HOLMIUM LASER FOR TREATMENT OF FARSIGHTEDNESS
SUMMIT TECHNOLOGY ANNOUNCES FDA APPROVAL TO BEGIN SECOND PHASE OF U.S. CLINICAL TRIALS USING HOLMIUM LASER FOR TREATMENT OF FARSIGHTEDNESS
FDA CLEARS LASER FOR TREATMENT OF UROLOGIC DISORDERS
LASER CLEARED FOR ENDONASAL PROCEDURES
FDA ACCEPTS SUMMIT'S APPLICATION TO COMMERCIALLY MARKET EXCIMER LASER SYSTEMS FOR TREATMENT OF MYOPIA
FDA ACCEPTS SUMMIT'S APPLICATION TO COMMERCIALLY MARKET EXCIMER LASER SYSTEMS FOR TREATMENT OF MYOPIA
SUMMIT TECHNOLOGY RECEIVES TWO FDA APPROVALS TO BEGIN PHASE III CLINICAL TRIALS USING HOLMIUM LASER FOR TREATMENT OF FARSIGHTEDNESS & ASTIGMATISM
SUMMIT RECEIVES FDA APPROVAL TO SELL EXCIMER LASER SYSTEM FOR PTK
Eclipse Submits PMA Application to FDA for Transmyocardial Revascularization

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters